Dividends & Buybacks ·
Haleon plc purchased 1,569,800 ordinary shares for cancellation under its buyback programme on August 17 and 18, 2026
HLNHaleon plc
Haleon plc purchased 1,569,800 ordinary shares for cancellation under its buyback programme on August 17 and 18, 2026. The company has now completed the £500 million share buyback programme originally announced on March 12, 2026. Since the start of the year, Haleon repurchased a total of 144,012,239 shares, all of which were cancelled. Following these transactions, the registered share capital stands at 8,808,341,409 ordinary shares, with 11,807,443 held as treasury shares and 8,796,533,966 carrying voting rights. Haleon plc operates in the consumer healthcare industry, manufacturing and selling over-the-counter medicines and health supplements under brands such as Advil, Panadol, and Sensodyne.